Full metadata record

DC FieldValueLanguage
dc.contributor.author윤호종-
dc.contributor.author곽연의-
dc.contributor.author최승혜-
dc.contributor.author조한나-
dc.contributor.author김남두-
dc.contributor.author심태보-
dc.date.accessioned2016-04-04T17:00:03Z-
dc.date.available2016-04-04T17:00:03Z-
dc.date.issued201601-
dc.identifier.citationVOL 59, NO 1, 358-373-
dc.identifier.issn00222623-
dc.identifier.other46407-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/58827-
dc.description.abstractAberrant RET kinase signaling plays critical roles in several human cancers such as thyroid carcinoma. The gatekeeper mutants (V804L or V804M) of RET are resistant to currently approved RET inhibitors such as cabozantinib and vandetanib. We, for the first time, report a highly selective and extremely potent RET inhibitor, 6i rationally designed. Compound 6i inhibits strongly RET gatekeeper mutants and other clinically relevant RET mutants as well as wt-RET. This substance also significantly suppresses growth of thyroid cancer-derived TT cell lines and Ba/F3 cells transformed with various RET mutants. Docking studies reveal that the isoxazole moiety in 6i is responsible for binding affinity improvement by providing additional site for H-bonding with Lys758. Also, 6i not only substantially blocks cellular RET autophosphorylation and its downstream pathway, it markedly induces apoptosis and anchorage-independent growth inhibition in TT cell lines while having no effect on normal thyroid Nthy ori-3-1 cells.-
dc.publisherJournal of medicinal chemistry-
dc.subjectRet-
dc.titleA Pyrazolo[3,4?d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants-
dc.typeArticle-
Appears in Collections:
KIST Publication > Article
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE